SEC Form 4 · accession 0001654954-17-005710
TG THERAPEUTICS, INC. · TGTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael S Weiss
Officer — CEO and President
Period of report
Jun 19, 2017
Accepted (ET)
Jun 19, 2017 · 6:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001316
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1 | Jun 19, 2017 | G | 350,000 | $0.00 | D | 9,795,917 | D | |
| COMMON STOCK (RESTRICTED)F2,F3,F4 | Jun 19, 2017 | A | 834,877 | $0.00 | A | 10,630,794 | I | See Note 4 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects the transfer of 350,000 shares of TG Therapeutics stock to the Weiss Family and Descendants Trust.
- F2Reflects an annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provides the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on the date of grant; provided however, if the market capitalization threshold is met prior to June 30, 2018 then the shares shall vest on June 30, 2018.
- F3Included in Mr. Weiss' beneficial ownership are 4,910,010 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest.
- F4The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member.